Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness

BACKGROUND: Treatment with tumor-Infiltrating Lymphocytes (TIL) is an innovative therapy for advanced melanoma with promising clinical phase I/II study results and likely beneficial cost-effectiveness. As a randomized controlled trial on the effectiveness of TIL therapy in advanced melanoma compared...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindenberg, Melanie, Retèl, Valesca, Rohaan, Maartje, van den Berg, Joost, Haanen, John, van Harten, Wim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393723/
https://www.ncbi.nlm.nih.gov/pubmed/32736535
http://dx.doi.org/10.1186/s12885-020-07166-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393723/
https://www.ncbi.nlm.nih.gov/pubmed/32736535
http://dx.doi.org/10.1186/s12885-020-07166-9

Ejemplares similares